Training Example: Evolus – Review the Data, Give Your Score & Compare to the Real AI Evaluation

[IMG: Evolus Rewards Patient Loyalty Program]
[IMG: 1 Million User Logo]
ONE MILLION ENROLLEDCONSUMERSNow celebrating one million consumers in Evolus Rewards, the only co-branded patient loyalty program designed to help practices grow by rewarding every patient, every time.*$40 OffEVERY TREATMENT,EVERY TIME*Bring Evolus Rewards to Your PracticeEnroll to get $40 off Every Treatment*patients eligible once every 90 days

[H1] Clinical Studies
[IMG: Post preview image.]
[IMG: Post preview image.]
DERMATOLOGIC SURGERYVolume45-Issue11EVOLUS SPONSOREDNovember 2019
[H2] Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results From 2 Identical Phase III Studies
BACKGROUND PrabotulinumtoxinA is a 900-kDa botulinum toxin Type A produced by Clostridium botulinum.OBJECTIVE To investigate the efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines.CONCLUSION In these studies, a single dose of 20-U prabotulinumtoxinA was safe and effective for the treatment of glabellar lines.Read More
[IMG: Post preview image.]
[IMG: Post preview image.]
AESTHETIC SURGERY JOURNALVolume40-Issue4EVOLUS SPONSOREDApril 2020
[H2] A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Phase III, Non-Inferiority Study Comparing PrabotulinumtoxinA and OnabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients
BACKGROUND PrabotulinumtoxinA is a 900-kDa botulinum toxin type A produced by Clostridium botulinum.OBJECTIVE The authors sought to investigate the efficacy and safety of prabotulinumtoxinA compared to onabotulinumtoxinA and placebo for the treatment of glabellar lines.CONCLUSION A single treatment of 20 U prabotulinumtoxinA was safe and effective and noninferior to 20 U onabotulinumtoxinA for the treatment of moderate to severe glabellar lines.Read More
[IMG: Post preview image.]
[IMG: Post preview image.]
DERMATOLOGIC SURGERYVolume48-Issue6EVOLUS SPONSOREDJune 2022
[H2] PrabotulinumtoxinA for Treatment of Millennials With Moderate to Severe Glabellar Lines: Post Hoc Analyses of the Phase III Clinical Study Data
BACKGROUND The use of esthetic products by millennials is increasing, yet published clinical trial data in this population are limited.OBJECTIVE To compare the efficacy and safety of prabotulinumtoxinA for the treatment of moderate to severe glabellar lines in millennial and nonmillennial patients.CONCLUSION A single dose of 20U prabotulinumtoxinA administered for the treatment of glabellar lines was similarly well-tolerated by both millennials and nonmillennials; overall, it was more efficacious in millennials.Read More
[IMG: Post preview image.]
[IMG: Post preview image.]
DERMATOLOGIC SURGERYVolume47-Issue4EVOLUS SPONSOREDApril 2021
[H2] PrabotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines in Adult Patients With Skin of Color: Post Hoc Analyses of the US Phase III Clinical Study Data
BACKGROUND Limited US clinical data are available on the use of aesthetic products in patients with skin of color (SOC).OBJECTIVE To compare the efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in patients with and without SOC.CONCLUSION A single dose of 20U prabotulinumtoxinA was well tolerated and similar in effectiveness in patients with and without SOC for the treatment of glabellar lines.Read More
[IMG: Post preview image.]
[IMG: Post preview image.]
AESTHETIC SURGERY JOURNALVolume42-Issue12EVOLUS SPONSOREDDecember 2022
[H2] PrabotulinumtoxinA vs OnabotulinumtoxinA for the Treatment of Adult Males With Moderate to Severe Glabellar Lines: Post-hoc Analyses of the Phase III Clinical Study Data
BACKGROUND Despite a growing interest among men in cosmetic procedures such as botulinum toxin, comparator clinical trial data in this population are limited.OBJECTIVE The authors sought to compare the efficacy and safety of prabotulinumtoxinA and onabotulinumtoxinA for the treatment of males with moderate to severe glabellar lines.CONCLUSION The percentages of patients who met the definition of a responder were higher at almost all time points examined for prabotulinumtoxinA-treated males. Despite the high level of consistency across all measures, differences between the 2 treatment groups did not reach statistical significance. Further study is warranted to establish if these post-hoc analyses observations are reproducible in a larger male patient population.Read More
[IMG: Post preview image.]
[IMG: Post preview image.]
AESTHETIC SURGERY JOURNALVolume41-Issue12EVOLUS SPONSOREDDecember 2021
[H2] The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients
BACKGROUND PrabotulinumtoxinA is a 900-kDa botulinum toxin type A produced by Clostridium botulinum.OBJECTIVE The authors sought to investigate the safety of prabotulinumtoxinA for treatment of glabellar lines.CONCLUSION The safety of RTs of 20 U of prabotulinumtoxinA for moderate to severe glabellar lines was first established in this early phase II study based on a broad range of outcomes.Read More
[IMG: Post preview image.]
[IMG: Post preview image.]
AESTHETIC SURGERY JOURNALVolume41-Issue12EVOLUS SPONSOREDDecember 2021
[H2] The Second of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients
BACKGROUND PrabotulinumtoxinA is a 900-kDa botulinum toxin type A produced by Clostridium botulinum.OBJECTIVE The authors sought to investigate the safety of prabotulinumtoxinA for treatment of glabellar lines.CONCLUSION The safety of RTs of 20 U of prabotulinumtoxinA for moderate to severe glabellar lines was confirmed in this second phase II study based on a broad range of outcomes.Read More
[IMG: Post preview image.]
[IMG: Post preview image.]
DERMATOLOGIC SURGERYVolume50-Issue9SEVOLUS SPONSOREDSeptember 2024
[H2] Botulinum Toxin Accessory Proteins: Are They Just an Accessory?
BACKGROUND Botulinum neurotoxins produced by Clostridium botulinum consist of a complex of a core neurotoxin protein and one or more nontoxin accessory proteins. The accessory proteins are generally thought to protect the neurotoxin from the gastric environment in botulism poisoning, dissociating away upon absorption. Other than their questionable immunogenicity, they are rarely mentioned in botulinum toxin therapy.OBJECTIVE To review evidence that accessory proteins potentially play a role in neurotoxin activity.CONCLUSION Accessory proteins may play a role in the efficacy of botulinum toxin and could remain complexed to the neurotoxin for longer than previously reported.Read More
[IMG: Post preview image.]
[IMG: Post preview image.]
JAMA DERMATOLOGYVolume50-Issue9SEVOLUS FUNDED*May 2025
[H2] Comparison of Botulinum Toxin A Formulations for Glabellar Strain Treatment in Women - A Double-Blind Randomized Clinical Trial
IMPORTANCE Multiple botulinum toxin A formulations were approved by the US Food and Drug Administration for treating the glabellar rhytids. A comparative quantitative evaluation of their effects on the glabella has not been conducted.OBJECTIVE To provide an objective quantitative assessment of the effect of 4 botulinum toxin A formulations on glabellar strain across using dynamic 3-dimensional photogrammetry.CONCLUSIONS AND RELEVANCE This randomized clinical trial found that ABoNT/A and PBoNT/A displayed the most rapid onset of effect. The peak effect is similar across all toxins. When measuring strain at approximately 6 months, some toxins remain significant relative to their own baseline or compared with other specific toxins.*Funding was requested by all manufacturers. Evolus provided funding via an investigator-initiated trial grant.Read More
[IMG: Post preview image.]
[IMG: Post preview image.]
AESTHETIC SURGERY JOURNALVolume45-Issue5Symatese sponsored. Manuscript prepared by EvolusMay 2025
[H2] Long-term Safety and Effectiveness of Cold-Crosslinked Hyaluronic Acid Fillers: Multicenter, Randomized, Controlled, Double-Blind Study
BACKGROUND Evolysse Form (EVLF) and Evolysse Smooth (EVLS) (Symatese, Chaponost, France) are new hyaluronic acid fillers created using an innovative cold-crosslinking process.OBJECTIVE The authors of this study aim to collect safety and effectiveness data on new cold-crosslinked fillers to support the US approval for the correction of moderate-to-severe dynamic facial wrinkles and folds.CONCLUSION The new cold-crosslinked fillers were shown to be safe and effective for correction of NLFs, with results lasting for 1 year.Read More

[H1] Contact Us
We are here for all of your questions and concerns.You can call our customer services line at 1-(877) 386-5871 during business hours or start a conversation below.Contact Us

Day 0 & Day 30Day 2Day 30Day 120Day 0 & Day 30Day 2Day 30Day 120Arielle
[IMG: Arielle]
[IMG: Arielle]
Thank you! Your submission has been received!Oops! Something went wrong while submitting the form.Arielle
[IMG: Arielle]
Arielle
[IMG: Arielle]
Arielle
[IMG: Arielle]
[IMG: Arielle]
David
[IMG: David]
[IMG: David]
Thank you! Your submission has been received!Oops! Something went wrong while submitting the form.David
[IMG: David]
David
[IMG: David]
David
[IMG: David]
[IMG: David]
Sarah
[IMG: Sarah]
[IMG: Sarah]
Thank you! Your submission has been received!Oops! Something went wrong while submitting the form.Sarah
[IMG: Sarah]
Sarah
[IMG: Sarah]
Sarah
[IMG: Sarah]
[IMG: Sarah]
Tajah
[IMG: Tajah]
[IMG: Tajah]
Thank you! Your submission has been received!Oops! Something went wrong while submitting the form.Tajah
[IMG: Tajah]
Tajah
[IMG: Tajah]
Tajah
[IMG: Tajah]
[IMG: Tajah]
Lisa
[IMG: Lisa]
[IMG: Lisa]
Thank you! Your submission has been received!Oops! Something went wrong while submitting the form.Lisa
[IMG: Lisa]
Lisa
[IMG: Lisa]
Lisa
[IMG: Lisa]
[IMG: Lisa]
Tia
[IMG: Tia]
[IMG: Tia]
Thank you! Your submission has been received!Oops! Something went wrong while submitting the form.Tia
[IMG: Tia]
Tia
[IMG: Tia]
Tia
[IMG: Tia]
[IMG: Tia]
Shai
[IMG: Shai]
[IMG: Shai]
Thank you! Your submission has been received!Oops! Something went wrong while submitting the form.Shai
[IMG: Shai]
Shai
[IMG: Shai]
Shai
[IMG: Shai]
[IMG: Shai]
Josephine
[IMG: Josephine]
[IMG: Josephine]
Thank you! Your submission has been received!Oops! Something went wrong while submitting the form.Josephine
[IMG: Josephine]
Josephine
[IMG: Josephine]
Josephine
[IMG: Josephine]
[IMG: Josephine]
Tugba
[IMG: Tugba]
[IMG: Tugba]
Thank you! Your submission has been received!Oops! Something went wrong while submitting the form.Tugba
[IMG: Tugba]
Tugba
[IMG: Tugba]
Tugba
[IMG: Tugba]
[IMG: Tugba]
ArielleDavidSarahTajahLisaTiaShaiJosephineTugbaSee More ResultsAt maximum frown. Actual patient. Results may vary.In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician-and patient-rated improvement in frown lines at Day 30.3In a study conducted in Europe and Canada, 54% of Jeuveau patients had a ≥1-grade improvement in frown lines at Day 2 based on physician assessment compared to 12% for placebo (secondary endpoint).2 In US studies, 46% and 56% had a ≥1-grade improvement in frown lines at Day 2 based on physician-assessment compared to 8% and 17% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be considered clinically meaningful.In US studies, 68% and 70% of Jeuveau patients had a 2-grade or better physician- and patient-rated improvement in frown lines at Day 30, compared to 1% for placebo.3In a study conducted in Europe and Canada, 58% of Jeuveau patients had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 13% for placebo (exploratory endpoint).2 In US studies, 65% and 57% had ≥1-grade improvement in frown lines at Day 120 based on physician assessment, compared to 8% and 13% for placebo (exploratory endpoint).3 Results based on a 1-grade improvement may not be clinically meaningful.